295 related articles for article (PubMed ID: 38317842)
1. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.
Wei J; Wang J; Chen X; Zhang L; Peng M
PeerJ; 2024; 12():e16819. PubMed ID: 38317842
[TBL] [Abstract][Full Text] [Related]
2. Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma.
Liu Z; Wang J; Li S; Li L; Li L; Li D; Guo H; Gao D; Liu S; Ruan C; Dang X
Front Immunol; 2022; 13():1076045. PubMed ID: 36591279
[TBL] [Abstract][Full Text] [Related]
3. Disulfidptosis and ferroptosis related genes predict prognosis and personalize treatment for hepatocellular carcinoma.
Liu JF; Huang L; Zhou XP; Li CR; Liu MF; Liang YH; Yu QH; Wu JR
Transl Cancer Res; 2024 Feb; 13(2):496-514. PubMed ID: 38482398
[TBL] [Abstract][Full Text] [Related]
4. Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.
Zhao J; Luo Z; Fu R; Zhou J; Chen S; Wang J; Chen D; Xie X
Eur J Med Res; 2023 Dec; 28(1):571. PubMed ID: 38057871
[TBL] [Abstract][Full Text] [Related]
5. Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy.
Long S; Chen Y; Wang Y; Yao Y; Xiao S; Fu K
Cancer Med; 2023 Jan; 12(2):2134-2147. PubMed ID: 35841206
[TBL] [Abstract][Full Text] [Related]
6. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
7. Machine learning- and WGCNA-mediated double analysis based on genes associated with disulfidptosis, cuproptosis and ferroptosis for the construction and validation of the prognostic model for breast cancer.
Xu L; Wang S; Zhang D; Wu Y; Shan J; Zhu H; Wang C; Wang Q
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16511-16523. PubMed ID: 37712959
[TBL] [Abstract][Full Text] [Related]
8. Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study.
Chen X; Liang Q; Zhou Y
Medicine (Baltimore); 2023 Oct; 102(40):e35423. PubMed ID: 37800779
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of ferroptosis-related prognostic risk model and immune landscape in hepatocellular carcinoma.
Tang F; Wang N
Immunobiology; 2023 Sep; 228(5):152723. PubMed ID: 37517112
[TBL] [Abstract][Full Text] [Related]
10. Ferroptosis-Related Genes with Regard to CTLA-4 and Immune Infiltration in Hepatocellular Carcinoma.
Xu J; Wu X; Wang X
Biochem Genet; 2023 Apr; 61(2):687-703. PubMed ID: 36094606
[TBL] [Abstract][Full Text] [Related]
11. Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile.
Wang T; Guo K; Zhang D; Wang H; Yin J; Cui H; Wu W
Int Immunopharmacol; 2023 Jul; 120():110368. PubMed ID: 37247499
[TBL] [Abstract][Full Text] [Related]
12. The cell death-related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinoma.
Du M; Qu Y; Qin L; Zheng J; Sun W
J Cell Mol Med; 2024 Apr; 28(7):e18168. PubMed ID: 38494848
[TBL] [Abstract][Full Text] [Related]
13. Constructed Risk Prognosis Model Associated with Disulfidptosis lncRNAs in HCC.
Jia X; Wang Y; Yang Y; Fu Y; Liu Y
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139458
[TBL] [Abstract][Full Text] [Related]
14. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
Xu L; Zheng Q; Liu W
BMC Cancer; 2022 Mar; 22(1):229. PubMed ID: 35236323
[TBL] [Abstract][Full Text] [Related]
15. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma.
Tang B; Zhu J; Li J; Fan K; Gao Y; Cheng S; Kong C; Zheng L; Wu F; Weng Q; Lu C; Ji J
Cell Commun Signal; 2020 Oct; 18(1):174. PubMed ID: 33115468
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma.
Dong W; Xie Y; Huang H
Front Endocrinol (Lausanne); 2022; 13():884777. PubMed ID: 35733776
[TBL] [Abstract][Full Text] [Related]
17. A prognostic risk model, tumor immune environment modulation, and drug prediction of ferroptosis and amino acid metabolism-related genes in hepatocellular carcinoma.
Ji L; Zhang Q; Cao Y; Liu L
Hum Cell; 2023 May; 36(3):1173-1189. PubMed ID: 36892792
[TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
Yan Z; He M; He L; Wei L; Zhang Y
Front Immunol; 2021; 12():723271. PubMed ID: 34925311
[TBL] [Abstract][Full Text] [Related]
19. Molecular subtypes of disulfidptosis-regulated genes and prognosis models for predicting prognosis, tumor microenvironment infiltration, and therapeutic response in hepatocellular carcinoma.
Qu J; Guan H; Zheng Q; Sun F
Int J Biol Macromol; 2024 Mar; 261(Pt 1):129584. PubMed ID: 38246443
[TBL] [Abstract][Full Text] [Related]
20. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
